New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
16:14 EDTCYCCCyclacel Pharmaceuticals reports Q2 EPS (22c), consensus (30c)
Reports cash and cash equivalents totaled $33.5M as of June 30. The company said, "We are pleased to report that we have enrolled over 70% of the required number of patients in our Phase 3 SEAMLESS trial in front-line AML. At present we have approximately 90 study centers open for enrollment in the US and Europe with additional sites to be added. We expect to complete SEAMLESS enrollment around the end of 2014 with data readout in the second half of 2015. Having surpassed enrollment of 300 patients, we expect the study's Data Safety Monitoring Board to perform the fourth periodic safety review once 60 days of follow-up have been observed."
News For CYCC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 17, 2014
06:18 EDTCYCCCyclacel downgraded to Market Perform from Outperform at JMP Securities
Subscribe for More Information
December 16, 2014
09:16 EDTCYCCOn The Fly: Pre-market Movers
Subscribe for More Information
07:41 EDTCYCCCyclacel Pharmaceuticals to host conference call
Subscribe for More Information
07:11 EDTCYCCCyclacel announces sapacitabine Phase 3 trial continues to final analysis
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use